

Best of SABCS 2022



OFFICIAL



Breast Cancer: Perspectives

Ahmad Awada MD, PhD

Head of Oncology Medicine Department

Institut Jules Bordet - Université Libre de Bruxelles

Brussels - Belgium



SABCS® is the owner of the Trademark for all content related to the SABCS® Symposium Material and any derivatives thereof.



SAN ANTONIO
BREAST
CANCER
SYMPOSIUM®



INSTITUT
JULES BORDET



LICENSED BY



Disclosures

Advisory role: Amgen, AstraZeneca, Bayer, Daiichi, Eisai, Genomic Health, Hengrui, Innate, Ipsen, Leo Pharma, Lilly, Merck, MSD, Novartis, Pfizer, Seattle Genetics

Speaker fees: Amgen, AstraZeneca, Bayer, Daiichi, Eisai, Genomic Health, Ipsen, Leo Pharma, Lilly, Merck, MSD, Novartis, Pfizer, Seattle Genetics

Research grants to my Institute: BMS, Roche

Perspectives

- **Systemic therapies**
- **New therapeutic concepts**
- **Specific groups of patients/ tumors**
- **Clinical research**
- **Public health**
- **Patients empowerment**
- **Molecular biology**

Perspectives: Systemic therapies

- **Post CDK4/6 inhibitors – New CDK inhibitors**
- **New endocrine agents (beyond SERDs, SERM,...)**
- **New ADCs (New targets/ payloads)**
- **The value of immunotherapy approaches**
- **New molecular-targeted therapies**
- **New agents targeting HRD in BC (Beyond PARP inh.) (e.g., Pol- theta inhibitors,...)**
- **...**

Perspectives: New therapeutic concepts

- **Management of patients with « liquid » metastases**
- **Management of oligometastases (objective = cure?!)**
- **De-escalation (optimisation) therapies (all disciplines!)**
- **Management of residual disease (all settings following neoadjuvant or metastatic treatments!)**

Perspectives: Focus of specific groups of patients/ tumors

- Rare breast tumors
- Elderly patients
- Premenopausal patients (e.g., a group of pts is still over-treated)
- Management of BC in young « fertile » patients
- ...

Perspectives: Clinical research

- **Bringing trials and innovations to the majority of patients (e.g. Spiderweb project, role of digital health,...)**
- **The need to reduce the administrative burden in clinical research**
- **New models of « pragmatic » clinical trials/ networks (e.g., OncoDistinct network,...)**
- **...**

Perspectives: Public health

- **Financial toxicity** → **The urgent need for a long-term strategy**
- **Optimisation of the access to innovations**
- **Role of stakeholders on oncology efficiency (e.g., via All Can, ...)**
and drugs development acceleration
- **Big data/ RWE,...**
- **...**

Perspectives: Patients empowerment

- In clinical practice and research
- Drug adherence
- « Alternative » therapeutic approaches
- Digital health and PROs
- Supportive care
- ...

Perspectives : Molecular biology

- **New hallmarks of cancer (epigenetic, metabolism, senescence, ...)**
- **Clinical implications of tumor heterogeneity and single cell genomics**
- **Critical review of biomarkers story for a new departure**
- **...**



Thank you !

Best of SABCS 2022

